Portage Biotech Inc - Asset Resilience Ratio
Portage Biotech Inc (PRTG) has an Asset Resilience Ratio of 0.00% as of March 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Portage Biotech Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2021)
This chart shows how Portage Biotech Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Portage Biotech Inc balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Portage Biotech Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Portage Biotech Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Portage Biotech Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Portage Biotech Inc Industry Peers by Asset Resilience Ratio
Compare Portage Biotech Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Portage Biotech Inc (2000–2021)
The table below shows the annual Asset Resilience Ratio data for Portage Biotech Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-03-31 | 0.00% | $0.00 | $174.86 Million | -- |
| 2020-03-31 | 0.04% | $68.00K | $173.17 Million | -0.02pp |
| 2019-03-31 | 0.06% | $103.00K | $173.72 Million | -0.46pp |
| 2018-03-31 | 0.52% | $52.00K | $10.00 Million | -97.83pp |
| 2017-03-31 | 98.35% | $58.91 Million | $59.90 Million | +95.31pp |
| 2012-03-31 | 3.04% | $228.12K | $7.51 Million | -17.29pp |
| 2011-03-31 | 20.32% | $1.96 Million | $9.62 Million | +7.27pp |
| 2010-03-31 | 13.05% | $1.33 Million | $10.22 Million | -55.48pp |
| 2009-03-31 | 68.52% | $864.47K | $1.26 Million | -0.83pp |
| 2008-03-31 | 69.36% | $3.53 Million | $5.09 Million | +19.67pp |
| 2007-03-31 | 49.69% | $2.87 Million | $5.78 Million | +17.07pp |
| 2006-03-31 | 32.62% | $1.53 Million | $4.68 Million | +31.11pp |
| 2005-03-31 | 1.51% | $63.15K | $4.20 Million | -25.91pp |
| 2000-03-31 | 27.42% | $480.04K | $1.75 Million | -- |
About Portage Biotech Inc
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors; PORT-6, a highly selective A2A receptor antagonist, which is in phase 1a for the treatment of solid tumors; PORT-8, a dual inhibitor … Read more